Written and maintained by CASRAI Editorial Board
Last updated
Suvoda is a clinical trial technology company whose best-known product is an interactive response technology (IRT) system, also called randomization and trial supply management (RTSM), used to randomize participants and manage investigational product in clinical trials. Since April 2025 the company has also included Greenphire, a maker of participant-payment and site-payment tools. This page explains what Suvoda is and does, how it relates to its products, and which other vendors operate in the same space. It is a neutral explainer, not an endorsement or a vendor comparison.
What Suvoda is
Suvoda describes itself as a clinical trial technology company serving patients, study sites, contract research organizations (CROs) and sponsors. According to the investor press release on the 2025 merger, Suvoda was founded in 2013 to build software for trial supply and randomization, consent and patient data collection, with a focus on oncology, central nervous system (CNS) and rare-disease trials. It describes itself as headquartered outside Philadelphia.
The product it is most associated with is its IRT, which Suvoda’s own materials treat as the same thing as RTSM. Suvoda’s RTSM/IRT product page says the two terms refer to the same category of clinical trial software and describes it as managing participant randomization, drug assignment and supply chain logistics.
What an IRT or RTSM system does in a trial
An IRT system is the software a trial uses to decide which treatment arm a participant is assigned to and which physical investigational product kit goes to that participant. The functions typically associated with these systems are:
- Randomization and treatment allocation: assigning participants to treatment arms according to the protocol.
- Supply management: inventory tracking, resupply and compliance monitoring for investigational product.
- Blinding management: roles and permissions that keep treatment assignments hidden from people who must stay blinded, which matters in trials that use blinding or masking.
The generic concept, independent of any brand, is defined in the CASRAI dictionary entry Randomization and Trial Supply Management (RTSM). Sponsor responsibilities for supplying and handling investigational product are set out in ICH E6 good clinical practice (section 5.14 in the R2 numbering). For how sites handle the product once it arrives, see research pharmacy and investigational drug services.
Who runs it and what it covers
Ownership and the 2025 merger
Suvoda and Greenphire announced an agreement to merge on 13 January 2025, and the companies announced the merger complete on 24 April 2025. The combined company operates as Suvoda, and Greenphire continues as a product name. The lead investor is Thoma Bravo, with Bain Capital Tech Opportunities Fund and LLR Partners holding significant minority investments. Suvoda founder Jagath Wanninayake is chief executive. Greenphire was founded in 2008 and focuses on participant reimbursement, site payments and study budgeting.
Product map
Suvoda’s home page lists its offerings under one platform. They group as follows:
| Area | Suvoda product named on its site | What it relates to |
|---|---|---|
| Randomization and supply | RTSM (IRT) | Treatment assignment and investigational product supply, described above |
| Participant-reported data | eCOA | Collecting electronic clinical outcome assessments |
| Consent | eConsent | Delivering electronic informed consent |
| Payments and budgets | Greenphire Patient Payments, Greenphire Travel, Site Payments, Budgeting & Benchmarking | Participant reimbursement, travel, site payment and study budgeting |
| Participant and site experience | Scheduling, Patient app | Visit scheduling and participant-facing access |
The site also describes an AI assistant called Sofia, client services, systems integration and CRO partnerships. The home page headline says eight products but its navigation lists ten entries, so treat any exact product count with caution.
Scale, as stated by the company
These figures are Suvoda’s own claims, not independently audited: more than 6,000 trials conducted, with 65% in oncology, rare disease and CNS; more than 115 countries supported; and a statement that 34% of trials that earned FDA approval since 2024 ran on Suvoda.
Where to find the sign-in
Study team members who already have an account use the sign-in link on Suvoda’s official website, suvoda.com. This page does not cover sign-in steps. Participants who have questions about a trial should ask their study site.
Strengths and limits
What is documented
- It has been operating since 2013 and is owned by named private-equity investors, according to the 2025 merger release.
- One vendor can cover randomization and supply, eCOA, eConsent and payments, which is the pitch of the merger. Whether a single-vendor stack suits a given trial is a sponsor decision.
- Its stated focus is oncology, CNS and rare disease, where randomization and supply are often complex.
What is not established
- Performance claims such as trial counts and approval shares come from the vendor itself.
- How Suvoda compares with other IRT vendors on cost, speed or usability is not established here, so this page makes no ranking claim.
Alternatives
The following organizations are commonly named as providers of RTSM or IRT systems. The list shows that the category is contested; it is not a ranking and does not describe each vendor’s features.
| Vendor | Product or note |
|---|---|
| Oracle | Clinical One RTSM |
| IQVIA | RTSM / IRT |
| Medidata | Rave RTSM |
| Signant Health | IRT / RTSM |
| Veeva Systems | RTSM / IRT |
| 4G Clinical | RTSM / IRT |
| YPrime | IRT / RTSM |
| Almac Clinical Technologies | IRT / RTSM |
Vendor selection in a sponsor organization is part of broader clinical trial vendor management, which covers selection, oversight and audit of eClinical suppliers.
FAQ
What kind of company is Suvoda?
Suvoda is a private clinical trial technology company, founded in 2013 and based near Philadelphia. Since the April 2025 merger with Greenphire it offers randomization and supply (IRT/RTSM), eCOA, eConsent and payment tools under the Suvoda name.
Who are the top IRT vendors?
There is no authoritative ranking of IRT vendors, and published rankings differ. Vendors commonly named are listed in the table above, including Suvoda, Oracle, IQVIA, Medidata, Signant Health, Veeva, 4G Clinical, YPrime and Almac.
What software is used in clinical trials?
Trials typically combine several systems: IRT/RTSM for randomization and supply, electronic data capture for case report forms, eCOA for participant-reported outcomes, eConsent, a clinical trial management system and a trial master file. See clinical trial vendor management for how sponsors oversee these suppliers.
Is Suvoda a legitimate company?
Suvoda is a real operating company: it has been in business since 2013 and its 2025 merger with Greenphire was announced complete on 24 April 2025, with Thoma Bravo as lead investor. CASRAI does not issue endorsements or ratings of vendors. Anyone assessing a vendor for a trial should rely on the sponsor’s own qualification and audit process.
What is the relationship between Suvoda and Greenphire?
Greenphire, founded in 2008, merged with Suvoda in a transaction completed on 24 April 2025. The combined company operates as Suvoda, and Greenphire remains the name of its payment and travel products.
Sources
- Suvoda, company home page and product list, https://www.suvoda.com/, checked 2026-11-07.
- Suvoda, RTSM/IRT product page, https://www.suvoda.com/rtsm-irt-clinical-trial, checked 2026-11-07.
- Thoma Bravo, “Suvoda and Greenphire Announce Completion of Merger,” 24 April 2025, https://www.thomabravo.com/press-releases/suvoda-and-greenphire-announce-completion-of-merger, checked 2026-11-07.
- Applied Clinical Trials, “Suvoda and Greenphire Merge to Create Unified Technology Platform” (agreement announced 13 January 2025), https://www.appliedclinicaltrialsonline.com/view/suvoda-greenphire-merge-create-unified-technology-platform, checked 2026-11-07.
- ICH, E6(R2) Good Clinical Practice, section 5.14 (investigational product(s)), https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf, checked 2026-11-07.
